Last Updated: November 16, 2026

Details for Patent: 8,648,087

« Back to Dashboard


Which drugs does patent 8,648,087 protect, and when does it expire?

Patent 8,648,087 protects TUKYSA and is included in one NDA.

This patent has fifty-four patent family members in twenty-nine countries.

Summary for Patent: 8,648,087
Title:N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Abstract:This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
Inventor(s):Joseph P. Lyssikatos, Julie Marie Greschuk, Fredrik P. Marmsäter, Qian Zhao, D. David Hennings, Weidong Liu
Assignee: Array Biopharma Inc
Application Number:US12/085,048
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,648,087

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Seagen TUKYSA tucatinib TABLET;ORAL 213411-001 Apr 17, 2020 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Seagen TUKYSA tucatinib TABLET;ORAL 213411-002 Apr 17, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,648,087

PCT Information
PCT FiledNovember 15, 2006PCT Application Number:PCT/US2006/044431
PCT Publication Date:May 24, 2007PCT Publication Number: WO2007/059257

International Family Members for US Patent 8,648,087

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1971601 ⤷  Start Trial C01971601/01 Switzerland ⤷  Start Trial
European Patent Office 1971601 ⤷  Start Trial 301113 Netherlands ⤷  Start Trial
European Patent Office 1971601 ⤷  Start Trial CA 2021 00025 Denmark ⤷  Start Trial
European Patent Office 1971601 ⤷  Start Trial LUC00217 Luxembourg ⤷  Start Trial
European Patent Office 1971601 ⤷  Start Trial PA2021516 Lithuania ⤷  Start Trial
European Patent Office 1971601 ⤷  Start Trial 122021000042 Germany ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.